Martin Jelsma is a political scientist who has specialised in Latin America and international drugs policy. In 2005, he received the Alfred R. Lindesmith Award for Achievement in the Field of Scholarship, which stated that Jelsma "is increasingly recognized as one of, if not the, outstanding strategists in terms of how international institutions deal with drugs and drug policy."...
Tom Blickman is a Senior Project Officer at the Transnational Institute (TNI), based in Amsterdam. Since 1997, he has been working for TNI's Drugs & Democracy Programme, specializing in international drug control policy and the UN conventions, drug markets, alternative development, money laundering and organised crime. Tom is a regular speaker at international policy conferences and advises...
David Bewley Taylor is the founding Director of the Global Drug Policy Observatory at Swansea University, UK. He has been researching various aspects of drug policy for over twenty years with his main areas of interest being US drug policy, the UN and international drug policy and more recently counter narcotics strategies in Afghanistan....
David Bewley-Taylor, Martin Jelsma, Christopher Hallam
16 June 2014
Scheduling is mostly prioritised in its repressive pole, though present debates are increasingly highlighting the need to modify the balance of the system in order to affirm the importance of the principle of health.
State-level cannabis reforms have exposed the inability of the United States to abide by the terms of the legal bedrock of the global drug control system. It is calls for a conversation the US federal government wishes to avoid. The result is a new official position on the UN drugs treaties that, despite its seductively progressive tone, serves only to sustain the status quo and may cause damage beyond drug policy.
The UN General Assembly Special Session (UNGASS) on drugs is fast approaching 2016 and is an important opportunity to conduct a thorough and objective assessment of the international drug control system. This session will discuss remaining challenges, as well as opportunities for the way forward – in particular towards rebalancing current drug policies towards the core UN values of public health, human rights and development
Drug policy reform is currently higher on the international agenda than it has been in recent memory. With a United Nations General Assembly Special Session (UNGASS) on drugs set for 19-21 April 2016, the prominence of this issue will further increase. Significant legal and policy reforms at the national level have taken place in recent years that pose considerable challenges to the international legal framework for drug control, and beg important questions regarding states’ international legal obligations.
Alternative Development programmes, aimed at encouraging peasants to switch from growing illicit drugs-related crops, play an important role in UN drug control strategies. The record of success, however, is a questionable one. Decades of efforts to reduce global drug supply using a combination of developmental and repressive means, managed to shift production from one country to another, but have failed in terms of global impact.
Allow countries and regions more space for policy reform using and stretching the margins of the conventions. Strengthen alliances of like-minded nations to support one another and effectively coordinate efforts at the UN level through informal consultations and strategy meetings. Any crack in the global prohibition regime would not plunge the world into chaos immediately. We should not press for a new global straitjacket but for a model that respects cultural differences. We have to open up the debate about the wisdom of the conventions as they stand.
At the 49th Session of the Commission on Narcotic Drugs (CND), held in Vienna in March 2006, a draft resolution was tabled by the European Union (EU) to guide the process of evaluation of the implementation of political declaration and action plans of the 1998 UN General Assembly Special Session (UNGASS) in 2008. This briefing describes the fortunes of the resolution and its proposals to strengthen the upcoming UNGASS evaluation process. It explores how the resolution’s aims for more objective and transparent assessment were ultimately watered down. This was a result not only of opposition from states wary of transparency, objectivity and a possible re-evaluation of some current UN policies, but also the EU’s own approach to operating at the CND.
Produced by an Oscar-winning studio for the Global Drug Policy Program of the Open Society Institute, International Drug Policy: Animated Report 2009 highlights some of the disastrous effects of drug policy in recent years and proposes solutions for a way forward.
As the international community finalises the Political Declaration and work plan that will guide the next ten years of international drug policy, it is inconceivable and indeed unconscionable that support for scientifically proven, evidence-based harm reduction programmes will again be blocked. States must show responsible leadership and act in the best interests of public health and human rights, rather than the narrow and failed language of ‘a drug free world’. This issue is much bigger than ideology, semantics and intergovernmental wordplay. It is about saving lives.